Targeting group II Metabotropic Glutamate (mGlu) receptors for the treatment of psychosis associated with alzheimer's disease: Selective activation of mGlu2 receptors amplifies β-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective

Molecular Pharmacology

Volumn 79, Issue 3, 2011, Pages 618-626

  Caraci, Filippo ^a   Molinaro, Gemma ^b   Battaglia, Giuseppe ^b   Giuffrida, Maria Laura ^a,c   Riozzi, Barbara ^b   Traficante, Anna ^b   Bruno, Valeria ^b,e   Cannella, Milena ^b   Merlo, Sara ^a   Wang, Xushan ^f   Heinz, Beverly A ^f   Nisenbaum, Eric S ^f   Britton, Thomas C ^f   Drago, Filippo ^a   Sortino, Maria Angela ^a   Copani, Agata ^a,d   Nicoletti, Ferdinando ^b,e  

^a UNIVERSITY OF CATANIA   (Italy)

^b IRCCS NEUROMED   (Italy)

^c NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

^d CNR   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 BROMOPYRIMIDIN 2 YL) N (2,4 DICHLOROBENZYL)PYRROLIDIN 3 AMINE METHANESULFONATE HYDRATE; 2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; AMYLOID BETA PROTEIN; LY 2389575; LY 566332; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; N (4' CYANO BIPHENYL 3 YL) N (3 PYRIDINYLMETHYL)ETHANESULFONAMIDE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CELL VIABILITY; DRUG ANTAGONISM; DRUG TARGETING; GENE EXPRESSION; MOUSE; NERVE CELL CULTURE; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RAT;

ALZHEIMER DISEASE; AMINO ACIDS; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIPSYCHOTIC AGENTS; ASTROCYTES; BICYCLO COMPOUNDS, HETEROCYCLIC; CELLS, CULTURED; MICE; MICE, KNOCKOUT; NEURONS; NEUROPROTECTIVE AGENTS; PSYCHOTIC DISORDERS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFONAMIDES; TRANSFORMING GROWTH FACTOR BETA1; XANTHENES;

EID: 79951975389     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.067488     Document Type: Article

References (42)

1. Arosio B, Bergamaschini L, Galimberti L, La Porta C, Zanetti M, Calabresi C, Scarpini E, Annoni G, and Vergani C (2007) +10 T/C polymorphisms in the gene of transforming growth factor-β1 are associated with neurodegeneration and its clinical evolution. Mech Ageing Dev 128:553-557. (Pubitemid 47498523)
2. Ashe KH and Zahs KR (2010) Probing the biology of Alzheimer's disease in mice. Neuron 66:631-645.
3. Bruno V, Battaglia G, Casabona G, Copani A, Caciagli F, and Nicoletti F (1998) Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-β. J Neurosci 18:9594-9600. (Pubitemid 28543740)
4. Bullock R (2005) Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings. Curr Med Res Opin 21:1-10.
5. Caraci F, Battaglia G, Bruno V, Bosco P, Carbonaro V, Giuffrida ML, Drago F, Sortino MA, Nicoletti F, and Copani A (2009) TGF-β1 pathway as a new target for neuroprotection in Alzheimer's disease. CNS Neurosci Ther doi:10.1111/j.1755-5949.2009.00115.x.
6. Carter K, Dickerson J, Schoepp DD, Reilly M, Herring N, Williams J, Sallee FR, Sharp JW, and Sharp FR (2004) The mGlu2/3 receptor agonist LY379268 injected into cortex or thalamus decreases neuronal injury in retrosplenial cortex produced by NMDA receptor antagonist MK-801: possible implications for psychosis. Neuropharmacology 47:1135-1145. (Pubitemid 39572705)
7. Cartmell J, Monn JA, and Schoepp DD (2000) Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology 148:423-429. (Pubitemid 30169761)
8. Ciceroni C, Mosillo P, Mastrantoni E, Sale P, Ricci-Vitiani L, Biagioni F, Stocchi F, Nicoletti F, and Melchiorri D (2010) mGLU3 metabotropic glutamate receptors modulate the differentiation of SVZ-derived neural stem cells towards the astrocytic lineage. Glia 58:813-822.
9. Conn PJ, Lindsley CW, and Jones CK (2009) Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci 30:25-31.
10. Copani A, Condorelli F, Caruso A, Vancheri C, Sala A, Giuffrida Stella AM, Canonico PL, Nicoletti F, and Sortino MA (1999) Mitotic signaling by β-amyloid causes neuronal death. FASEB J 13:2225-2234.
11. Copani A, Koh JY, and Cotman CW (1991) Beta-amyloid increases neuronal susceptibility to injury by glucose deprivation. Neuroreport 2:763-765.
12. Corti C, Battaglia G, Molinaro G, Riozzi B, Pittaluga A, Corsi M, Mugnaini M, Nicoletti F, and Bruno V (2007) The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/ neuroprotection. J Neurosci 27:8297-8308. (Pubitemid 47219630)
13. D'Onofrio M, Cuomo L, Battaglia G, Ngomba RT, Storto M, Kingston AE, Orzi F, De Blasi A, Di Iorio P, Nicoletti F, et al. (2001) Neuroprotection mediated by glial group-II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol-3-kinase pathways. J Neurochem 78:435-445. (Pubitemid 32729972)
14. Fell MJ, Svensson KA, Johnson BG, and Schoepp DD (2008) Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4- amino- 2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther 326:209-217. (Pubitemid 351872145)
15. Fraley ME (2009) Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Expert Opin Ther Pat 19:1259-1275.
16. Gill SS, Rochon PA, Herrmann N, Lee PE, Sykora K, Gunraj N, Normand SL, Gurwitz JH, Marras C, Wodchis WP, et al. (2005) Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 330:445.
17. Giuffrida ML, Caraci F, Pignataro B, Cataldo S, De Bona P, Bruno V, Molinaro G, Pappalardo G, Messina A, Palmigiano A, et al. (2009) Beta-amyloid monomers are neuroprotective. J Neurosci 29:10582-10587.
18. Giuffrida ML, Grasso G, Ruvo M, Pedone C, Saporito A, Marasco D, Pignataro B, Cascio C, Copani A, and Rizzarelli E (2007) Aβ(25-35) and its C- and/or N-blocked derivatives: copper driven structural features and neurotoxicity. J Neurosci Res 85:623-633.
19. Hardy J (2009) The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 110:1129-1134.
20. Herrmann N and Lanctôt KL (2005) Do atypical antipsychotics cause stroke? CNS Drugs 19:91-103. (Pubitemid 40321762)
21. Herrup K, Neve R, Ackerman SL, and Copani A (2004) Divide and die: cell cycle events as triggers of nerve cell death. J Neurosci 24:9232-9239. (Pubitemid 39426158)
22. Johnson MP, Barda D, Britton TC, Emkey R, Hornback WJ, Jagdmann GE, McKinzie DL, Nisenbaum ES, Tizzano JP, and Schoepp DD (2005) Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology 179:271-283. (Pubitemid 40576715)
23. Kim SH, Fraser PE, Westaway D, St George-Hyslop PH, Ehrlich ME, and Gandy S (2010) Group II metabotropic glutamate receptor stimulation triggers production and release of Alzheimer's amyloid(β)42 from isolated intact nerve terminals. J Neurosci 30:3870-3875.
24. Koh JY, Yang LL, and Cotman CW (1990) Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res 533:315-320. (Pubitemid 20377714)
25. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, et al. (1998) Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448-6453.
26. Lee HG, Ogawa O, Zhu X, O'Neill MJ, Petersen RB, Castellani RJ, Ghanbari H, Perry G, and Smith MA (2004) Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimer's disease. Acta Neuropathol 107:365-371. (Pubitemid 38477364)
27. Lee HG, Zhu X, Casadesus G, Pallàs M, Camins A, O'Neill MJ, Nakanishi S, Perry G, and Smith MA (2009) The effect of mGluR2 activation on signal transduction pathways and neuronal cell survival. Brain Res 1249:244-250.
28. Leucht S, Corves C, Arbter D, Engel RR, Li C, and Davis JM (2009) Secondgeneration versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31-41.
29. Lieberman JA (1999) Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry 46:729-739.
30. Lieberman JA (2007) Neuroprotection: a new strategy in the treatment of schizophrenia. Neurobiological basis of neurodegeneration and neuroprotection. CNS Spectr 12(Suppl 18):4-6.
31. Mazzucco S, Cipriani A, Barbui C, and Monaco S (2008) Antipsychotic drugs and cerebrovascular events in elderly patients with dementia: a systematic review. Mini Rev Med Chem 8:776-783.
32. Niswender CM and Conn PJ (2010) Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 50:295-322.
33. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, et al. (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 13:1102-1107. (Pubitemid 47517511)
34. Pérez-Neri I, Ramírez-Bermúdez J, Montes S, and Ríos C (2006) Possible mechanisms of neurodegeneration in schizophrenia. Neurochem Res 31:1279-1294.
35. Querfurth HW and LaFerla FM (2010) Alzheimer's disease. N Engl J Med 362:329-344.
36. Recupero PR and Rainey SE (2007) Managing risk when considering the use of atypical antipsychotics for elderly patients with dementia-related psychosis. J Psychiatr Pract 13:143-152. (Pubitemid 46809446)
37. Rorick-Kehn LM, Hart JC, and McKinzie DL (2005) Pharmacological characterization of stress-induced hyperthermia in DBA/2 mice using metabotropic and ionotropic glutamate receptor ligands. Psychopharmacology 183:226-240. (Pubitemid 41609275)
38. Rund BR (2009) Is schizophrenia a neurodegenerative disorder? Nord J Psychiatry 63:196-201.
39. Schoepp DD, Jane DE, and Monn JA (1999) Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38:1431-1476. (Pubitemid 29457728)
40. Swanson CJ and Schoepp DD (2003) A role for noradrenergic transmission in the actions of phencyclidine and the antipsychotic and antistress effects of mGlu2/3 receptor agonists. Ann N Y Acad Sci 1003:309-317. (Pubitemid 38083064)
41. Tesseur I, Zou K, Esposito L, Bard F, Berber E, Can JV, Lin AH, Crews L, Tremblay P, Mathews P, et al. (2006) Deficiency in neuronal TGF-β signaling promotes neurodegeneration and Alzheimer's pathology. J Clin Invest 116:3060-3069. (Pubitemid 44684491)
42. Trifirò G, Spina E, and Gambassi G (2009) Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile? Pharmacol Res 59:1-12.